RedHill Biopharma Ltd. (NASDAQ:RDHL) Receives Consensus Recommendation of “Buy” from Analysts

RedHill Biopharma Ltd. (NASDAQ:RDHL) has been assigned an average rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $21.75.

RDHL has been the topic of several analyst reports. Zacks Investment Research raised RedHill Biopharma from a “strong sell” rating to a “hold” rating in a report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $26.00 target price on shares of RedHill Biopharma in a report on Monday, May 31st. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of RedHill Biopharma in a report on Wednesday. WBB Securities lowered RedHill Biopharma from a “strong-buy” rating to a “buy” rating and dropped their target price for the stock from $17.00 to $16.00 in a report on Friday, May 28th. Finally, Roth Capital reaffirmed a “buy” rating on shares of RedHill Biopharma in a report on Tuesday, June 1st.

Shares of RDHL stock traded down $0.01 during mid-day trading on Friday, reaching $7.18. The stock had a trading volume of 3,736 shares, compared to its average volume of 282,647. The business has a fifty day moving average of $6.87. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.55 and a current ratio of 1.69. RedHill Biopharma has a 1-year low of $5.90 and a 1-year high of $11.52.

RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings data on Wednesday, May 26th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.29. The business had revenue of $20.58 million for the quarter, compared to analyst estimates of $22.37 million. RedHill Biopharma had a negative return on equity of 251.48% and a negative net margin of 97.62%. Sell-side analysts forecast that RedHill Biopharma will post -1.48 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new position in shares of RedHill Biopharma in the first quarter valued at approximately $136,000. Great Point Partners LLC purchased a new position in shares of RedHill Biopharma in the first quarter valued at approximately $5,163,000. Psagot Investment House Ltd. purchased a new position in shares of RedHill Biopharma in the first quarter valued at approximately $1,402,000. Cubist Systematic Strategies LLC purchased a new position in shares of RedHill Biopharma in the first quarter valued at approximately $98,000. Finally, DAFNA Capital Management LLC purchased a new position in shares of RedHill Biopharma in the first quarter valued at approximately $3,337,000. Institutional investors and hedge funds own 22.82% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Featured Story: What are trading strategies for the 52-week high/low?

Analyst Recommendations for RedHill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.